Literature DB >> 2579098

Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes.

S Seto, C J Carrera, M Kubota, D B Wasson, D A Carson.   

Abstract

Deoxyadenosine has been implicated as the toxic metabolite causing profound lymphopenia in immunodeficient children with a genetic deficiency of adenosine deaminase (ADA), and in adults treated with the potent ADA inhibitor deoxycoformycin. However, the biochemical basis for deoxyadenosine toxicity toward lymphocytes remains controversial. The present experiments have examined in detail the sequential metabolic changes induced in nondividing human peripheral blood lymphocytes by incubation with deoxyadenosine plus deoxycoformycin, or with 2-chlorodeoxyadenosine (CdA), an ADA resistant deoxyadenosine congener with anti-leukemic and immunosuppressive properties. The lymphotoxic effect of deoxyadenosine and CdA required their phosphorylation, and was inhibited by deoxycytidine. As early as 4 h after exposure to the deoxynucleosides, strand breaks in lymphocyte DNA began to accumulate, and RNA synthesis decreased. These changes were followed by a significant fall in intracellular NAD levels at 8 h, a drop in ATP pools at 24 h, and cell death by 48 h. Incubation of the lymphocytes with 5 mM nicotinamide, a NAD precursor and an inhibitor of poly(ADP-ribose) synthetase, prevented NAD depletion. The nicotinamide treatment also rendered the lymphocytes highly resistant to deoxyadenosine and CdA toxicity, without altering dATP formation or the accumulation of DNA strand breaks. The poly(ADP-ribose) synthetase inhibitor 3-aminobenzamide exerted a similar although less potent effect. These results suggest that NAD depletion, probably triggered by poly(ADP-ribose) formation, is the principle cause of death in normal resting human lymphocytes exposed to deoxyadenosine plus deoxycoformycin, or to CdA.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2579098      PMCID: PMC423498          DOI: 10.1172/JCI111710

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  51 in total

1.  Fractionation of DNA from mammalian cells by alkaline elution.

Authors:  K W Kohn; L C Erickson; R A Ewig; C A Friedman
Journal:  Biochemistry       Date:  1976-10-19       Impact factor: 3.162

2.  Pyridine nucleotide levels as a function of growth in normal and transformed 3T3 cells.

Authors:  E L Jacobson; M K Jacobson
Journal:  Arch Biochem Biophys       Date:  1976-08       Impact factor: 4.013

3.  The rate of strand separation in alkali of DNA of irradiated mammalian cells.

Authors:  B Rydberg
Journal:  Radiat Res       Date:  1975-02       Impact factor: 2.841

4.  The deoxyribonucleoside 5'-triphosphate (dATP and dTTP) pool in phytohemagglutinin-stimulated and non-stimulated human lymphocytes.

Authors:  B Munch-Petersen; G Tyrsted; B Dupont
Journal:  Exp Cell Res       Date:  1973-06       Impact factor: 3.905

5.  An improved cycling assay for nicotinamide adenine dinucleotide.

Authors:  C Bernofsky; M Swan
Journal:  Anal Biochem       Date:  1973-06       Impact factor: 3.365

6.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity.

Authors:  E R Giblett; J E Anderson; F Cohen; B Pollara; H J Meuwissen
Journal:  Lancet       Date:  1972-11-18       Impact factor: 79.321

7.  Native and denatured DNA, cross-linked and palindromic DNA and circular covalently-closed DNA analysed by a sensitive fluorometric procedure.

Authors:  A R Morgan; D E Pulleyblank
Journal:  Biochem Biophys Res Commun       Date:  1974-11-27       Impact factor: 3.575

8.  DNA strand breaks induced in human T-lymphocytes by the combination of deoxyadenosine and deoxycoformycin.

Authors:  L Brox; A Ng; E Pollock; A Belch
Journal:  Cancer Res       Date:  1984-03       Impact factor: 12.701

9.  Pyridine nucleotide metabolism in mammalian cells in culture.

Authors:  D Hillyard; M C Rechsteiner; B M Olivera
Journal:  J Cell Physiol       Date:  1973-10       Impact factor: 6.384

10.  The pathway of biosynthesis of nicotinamide-adenine dinucleotide in rat mammary gland.

Authors:  A L Greenbaum; S Pinder
Journal:  Biochem J       Date:  1968-03       Impact factor: 3.857

View more
  68 in total

Review 1.  Treatment of Erdheim-Chester disease with cladribine: a rational approach.

Authors:  C Myra; L Sloper; P J Tighe; R S McIntosh; S E Stevens; R H S Gregson; M Sokal; A P Haynes; R J Powell
Journal:  Br J Ophthalmol       Date:  2004-06       Impact factor: 4.638

2.  Apoptosis in human thymocytes after treatment with glucocorticoids.

Authors:  M A Nieto; A González; F Gambón; F Díaz-Espada; A López-Rivas
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

3.  Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP.

Authors:  Kumudha Balakrishnan; Christine M Stellrecht; Davide Genini; Mary Ayres; William G Wierda; Michael J Keating; Lorenzo M Leoni; Varsha Gandhi
Journal:  Blood       Date:  2005-02-17       Impact factor: 22.113

4.  Insights into thymic purine metabolism and adenosine deaminase deficiency revealed by transgenic mice overexpressing ecto-5'-nucleotidase (CD73).

Authors:  R Resta; S W Hooker; A B Laurent; S M Jamshedur Rahman; M Franklin; T B Knudsen; N L Nadon; L F Thompson
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

5.  Additional treatment with 2-Chloro-2-Deoxyadenosine during consolidation in children with high-risk acute myeloid leukemia does not improve survival.

Authors:  U Creutzig; M N Dworzak; M Zimmermann; J-P Bourquin; B Gruhn; G Fleischhack; N Graf; T Klingebiel; B Kremens; T Lehrnbecher; C von Neuhoff; A V Stackelberg; J Starý; D Reinhardt
Journal:  Leukemia       Date:  2015-04-14       Impact factor: 11.528

Review 6.  Hairy cell leukemia: clinical features and therapeutic advances.

Authors:  B C Lembersky; H M Golomb
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

7.  Human autoantibodies to poly(adenosine diphosphate-ribose) polymerase.

Authors:  H Yamanaka; E H Willis; C A Penning; C L Peebles; E M Tan; D A Carson
Journal:  J Clin Invest       Date:  1987-09       Impact factor: 14.808

Review 8.  The optimal management of hairy cell leukaemia.

Authors:  R Gollard; T C Lee; L D Piro; A Saven
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

9.  Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma.

Authors:  Kensei Tobinai; Naokuni Uike; Yoshio Saburi; Takaaki Chou; Tetsuya Etoh; Masato Masuda; Fumio Kawano; Masao Matsuoka; Hirokuni Taguchi; Torahiko Makino; Yoshinobu Asano; Kazuo Tamura; Yasuo Ohashi
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

Review 10.  Pentostatin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.